Hints and tips:
Related Special Reports
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...AstraZeneca has a market capitalisation of £171bn....
...AstraZeneca makes 40 per cent of its sales in the US, like many European pharmaceutical companies, and it has sought to justify the increases by comparing Soriot’s pay with US pharma bosses....
...Late last year, AstraZeneca agreed to buy its first vaccine company, Icosovax, in a deal worth up to $1.1bn....
...The UK-based pharmaceutical group reported revenue of $12.7bn for the first quarter of 2024, an increase of 19 per cent, well ahead of consensus estimates of $11.9bn....
...The UK-based pharmaceutical group reported revenue of $12.7bn, well ahead of consensus estimates of $11.9bn....
...In February, the UK pharmaceuticals company hit a long-term sales target that once seemed out of reach....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...AstraZeneca has also sought to justify the changes by saying it is competing with US rivals. Like many European pharmaceutical companies, it makes a large proportion of sales in the US....
...Dato-DXd, which has been developed with Japanese pharmaceutical company Daiichi Sankyo, and Enhertu, another AstraZeneca treatment, are considered by analysts to be potentially high-earning drugs....
...AstraZeneca has promised to increase its dividend by 7 per cent this year, ahead of a key shareholder vote on pay for its long-standing chief executive Pascal Soriot....
...V-over-a-tee look, à la Neil Barrett....
...The chancellor said that AstraZeneca would invest £650mn in the UK to expand its manufacturing, after the government had encouraged the pharmaceutical company to increase its UK investment....
...AstraZeneca has agreed to buy oncology biotech Fusion Pharmaceuticals for $2.4bn, as it builds its capacity in a developing field of cancer care....
...The tribunal ruled that the largest company in the FTSE 100 discriminated against James Muir — a leading scientist who had been developing the pharmaceutical company’s drug, Truqap — on the basis of a disability...
...AstraZeneca’s jab developed with Oxford university was widely used across the world, but sales fell more than 99 per cent to just $12mn in 2023....
...AstraZeneca shareholders approved a potential £1.8mn pay rise for chief executive Pascal Soriot, despite a significant investor revolt against a pay increase advisers had called “excessive”....
...He insisted the market was “completely open” for investment from multinationals such as AstraZeneca, adding that the pharmaceutical industry did not suffer from the same kind of “tensions” with China faced...
...AstraZeneca has reported successful trial results for one of its top cancer drugs, in a boost to the drugmaker’s ambitions for its medication to be a treatment option for more than half of lung cancer patients...
...The writer is chair of AstraZeneca The AGM season is in full swing, and with it comes the usual set of controversies around remuneration....
...Munro’s play imagines the conversations — between Patrick and Katherine, between Katherine and the court, between Katherine and James V....
...The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them....
...The most famous chess match of all time Bobby Fischer v Boris Spassky in 1972, still casts its echoes....
...Sales of cancer drugs helped AstraZeneca to beat City expectations in 2023, as the FTSE 100 company forecast continued double-digit sales growth in 2024....
...The deal is expected to close in the first quarter of next year, AstraZeneca said....
International Edition